HBV

Hepatitis B
#Gene editing #Gene therapy #HBV #hepatitis #Phase I trial #Precision BioSciences

Positive early clinical signs for HBV gene editing therapy

Precision BioSciences has announced positive initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.   The ELIMINATE-B trial is designed to investigate PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level… Read More

#Editor's Choice #News

Human liver
#American Association for the Study of Liver Diseases (AASLD) #DNA #Epigenomics #HBV #Liver disease #Tune Therapeutics #Viral hepatitis

Preclinical data suggests functional cure for HBV

Epigenome editing company Tune Therapeutics has showcased new data at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functional cure for chronic Hepatitis B Virus (HBV). Tune presented its lead HBV programme at the 2023 iteration of the… Read More

#News